Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Sirt3, a member of the family of nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases, mainly localizes at mitochondria and participates in regulation of multiple cellular processes through its effect on protein acetylation. In recent years, the role of protein acetylation in controlling autophagy, a process of self-degradation of cellular components in response to various stresses such as starvation and oxidative stress, has begun to emerge. The objective of this study was to determine whether Sirt3, as a mitochondrial deacetylase, affects the induction of mitochondrial autophagy (mitophagy), a process of the specific autophagic elimination of damaged mitochondria. In human glioma cell lines T98G and LN229 and breast cancer cell lines MCF-7 and MDAMB468, we showed that increased production of reactive oxygen species (ROS) and damaged mitochondria (decreased mitochondrial membrane potential, MMP) caused by hypoxia were accompanied by activation of autophagy, as evidenced by elevated amounts of LC3 II, Atg5 and Atg12-5 complex that were detected by western blot. Silencing of Sirt3 expression by RNA interference blunted the hypoxia-induced autophagic response, blocked the degradation of mitochondria marker COX IV, and further increased the accumulation of ROS, suggesting an involvement of this protein deacetylase in the induction of mitophagy. Silencing of Sirt3 expression also promoted apoptosis, as demonstrated by an increase in the population of tumor cells with Annexing V staining and by a reduction in MMP. Furthermore, our experiments showed that silencing of Sirt3 expression led to a down-regulation of the anti-apoptotic proteins mcl-1 and survivin, and MG132, a proteasome inhibitor, could rescue the down-regulation of these apoptosis-regulated proteins in the cells with silencing of Sirt3 expression. These results suggest that Sirt3 plays a role in stabilizing mcl-1 and survivin proteins, and that the down-regulation of mcl-1 and survivin by Sirt3 knockdown may account for the promotion of apoptosis in the cells treated with Sirt3-targeted siRNA. Similarly observations were made when these cell lines were subjected to starvation and oxidative stress (H2O2 treatment). Taken together, the results of the current study reveal Sirt3 as a novel regulator coupling mitophagy and apoptosis, two important cellular processes that determine survival and death of tumor cells. As alterations of mitophagy and apoptosis have been known to be associated with tumor development, progression, and therapy, our study on the role of Sirt3 in regulating these two cellular processes provides evidence for exploiting Sirt3 as a new drug target for prevention and treatment of cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4106. doi:1538-7445.AM2012-4106

Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer

Identification of small molecular inhibitors of SIRT3 by computational and biochemical approaches a potential target of breast cancer

Molecular Docking‐based Virtual Screening and Dynamics Simulation Study of Novel and Potential SIRT7 Inhibitors

Identification and Optimization of 3-Bromo-n'-(4-hydroxybenzylidene)-4-methylbenzohydrazide Derivatives As Mtor Inhibitors That Induce Autophagic Cell Death and Apoptosis in Triple-Negative Breast Cancer.

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance

Discovery of a Novel Small-Molecule Activator of SIRT3 That Inhibits Cell Proliferation and Migration by Apoptosis and Autophagy-Dependent Cell Death Pathways in Colorectal Cancer

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications

Abstract 1659: Development of HJC0152, its analogs and protein degraders to modulate STAT3 for triple-negative breast cancer therapy

Abstract 4106: Sirt3 controls the switch between mitophagy and apoptosis in tumor cells

Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy

Multi-omics Approaches Identify SF3B3 and SIRT3 As Candidate Autophagic Regulators and Druggable Targets in Invasive Breast Carcinoma

Context-dependent role of SIRT3 in cancer

Identification of Sirtuin 3, a Mitochondrial Protein Deacetylase, As a New Contributor to Tamoxifen Resistance in Breast Cancer Cells

Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis

Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

Abstract 7151: Targeting metabolic pathway in triple negative breast cancer with a small molecule inhibitor

Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD+ and substrate binding sites for the treatment of acute myeloid leukemia

SIRT3 Regulates Cell Proliferation and Apoptosis Related to Energy Metabolism in Non-Small Cell Lung Cancer Cells Through Deacetylation of NMNAT2.

Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti‐triple‐negative breast cancer efficacy in vitro and in vivo